Epidemiology of Varicella Hospitalizations in the United States, 1995–2005

To describe the impact of the varicella vaccination program on varicella-related hospitalizations (VRHs) in the United States, data from the Varicella Active Surveillance Project (VASP) were used to compare rates of hospitalization and rates of complications among patients hospitalized for varicella...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases Vol. 197; no. Supplement-2; pp. S120 - S126
Main Authors: Reynolds, Meredith A., Watson, Barbara M., Plott-Adams, Kelly K., Jumaan, Aisha O., Galil, Karin, Maupin, Teresa J., Zhang, John X., Seward, Jane F.
Format: Journal Article
Language:English
Published: United States The University of Chicago Press 01-03-2008
University of Chicago Press
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To describe the impact of the varicella vaccination program on varicella-related hospitalizations (VRHs) in the United States, data from the Varicella Active Surveillance Project (VASP) were used to compare rates of hospitalization and rates of complications among patients hospitalized for varicella-related conditions from 1995 to 2005. Of the 26,290 varicella cases reported between 1995 and 2005, 170 cases resulted in VRHs, including 1 case that resulted in death. Both VRH rates per 100,000 population and complications during VRH per 100,000 population decreased significantly between the early vaccination period (1995–1998) and the middle/late vaccination period (1999–2005). Infants and adults were at highest risk for VRH, and having been vaccinated against varicella was a protective factor. Varicella vaccination may have prevented a significant number of VRHs. The fact that 4 vaccinated children required hospitalization for varicella-related complications demonstrates that 1 dose of varicella vaccine does not prevent serious disease in all cases, even among previously healthy children.
Bibliography:Present affiliation: Idenix Pharmaceuticals, Cambridge, Massachusetts.
istex:50BC391A65FE3B920BC32F36246E2E37A23E4519
ark:/67375/HXZ-RHMC4JM3-K
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-1899
1537-6613
DOI:10.1086/522146